Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: protocol and statistical considerations.

Reutens AT, Jandeleit-Dahm K, Thomas M, Bach LA, Colman PG, Davis TME, D'Emden M, Ekinci EI, Fulcher G, Hamblin PS, Kotowicz MA, MacIsaac RJ, Morbey C, Simmons D, Soldatos G, Wittert G, Wu T, Cooper ME, Shaw JE.

Contemp Clin Trials. 2019 Nov 15:105892. doi: 10.1016/j.cct.2019.105892. [Epub ahead of print]

PMID:
31740428
2.

Endothelial or vascular smooth muscle cell-specific expression of human NOX5 exacerbates renal inflammation, fibrosis and albuminuria in the Akita mouse.

Jha JC, Dai A, Holterman CE, Cooper ME, Touyz RM, Kennedy CR, Jandeleit-Dahm KAM.

Diabetologia. 2019 Sep;62(9):1712-1726. doi: 10.1007/s00125-019-4924-z. Epub 2019 Jun 20.

PMID:
31222503
3.

Diabetes and Hypertension Differentially Affect Renal Catecholamines and Renal Reactive Oxygen Species.

Watson AMD, Gould EAM, Penfold SA, Lambert GW, Pratama PR, Dai A, Gray SP, Head GA, Jandeleit-Dahm KA.

Front Physiol. 2019 Apr 16;10:309. doi: 10.3389/fphys.2019.00309. eCollection 2019.

4.

Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?

Hanssen NM, Jandeleit-Dahm KA.

Diab Vasc Dis Res. 2019 Jul;16(4):303-309. doi: 10.1177/1479164119842339. Epub 2019 Apr 24.

5.

Reactive Oxygen Comes of Age: Mechanism-Based Therapy of Diabetic End-Organ Damage.

Elbatreek MH, Pachado MP, Cuadrado A, Jandeleit-Dahm K, Schmidt HHHW.

Trends Endocrinol Metab. 2019 May;30(5):312-327. doi: 10.1016/j.tem.2019.02.006. Epub 2019 Mar 27. Review.

6.

Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis.

Pickering RJ, Tikellis C, Rosado CJ, Tsorotes D, Dimitropoulos A, Smith M, Huet O, Seeber RM, Abhayawardana R, Johnstone EK, Golledge J, Wang Y, Jandeleit-Dahm KA, Cooper ME, Pfleger KD, Thomas MC.

J Clin Invest. 2019 Jan 2;129(1):406-421. doi: 10.1172/JCI99987. Epub 2018 Dec 10.

7.

A novel synthetic small molecule DMFO targets Nrf2 in modulating proinflammatory/antioxidant mediators to ameliorate inflammation.

Mathew G, Sharma A, Pickering RJ, Rosado CJ, Lemarie J, Mudgal J, Thambi M, Sebastian S, Jandeleit-Dahm KA, de Haan JB, Unnikrishnan MK.

Free Radic Res. 2018 Oct;52(10):1140-1157. doi: 10.1080/10715762.2018.1533636. Epub 2018 Nov 13.

PMID:
30422019
8.

Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis.

Brennan EP, Mohan M, McClelland A, de Gaetano M, Tikellis C, Marai M, Crean D, Dai A, Beuscart O, Derouiche S, Gray SP, Pickering R, Tan SM, Godson-Treacy M, Sheehan S, Dowdall JF, Barry M, Belton O, Ali-Shah ST, Guiry PJ, Jandeleit-Dahm K, Cooper ME, Godson C, Kantharidis P.

Diabetes. 2018 Dec;67(12):2657-2667. doi: 10.2337/db17-1317. Epub 2018 Sep 13.

9.

A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes.

Jha JC, Ho F, Dan C, Jandeleit-Dahm K.

Clin Sci (Lond). 2018 Aug 30;132(16):1811-1836. doi: 10.1042/CS20171459. Print 2018 Aug 31. Review.

PMID:
30166499
10.

Cardiovascular Disease and Diabetic Kidney Disease.

Maqbool M, Cooper ME, Jandeleit-Dahm KAM.

Semin Nephrol. 2018 May;38(3):217-232. doi: 10.1016/j.semnephrol.2018.02.003. Review.

PMID:
29753399
11.

Metabolic Karma-The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture.

Cooper ME, El-Osta A, Allen TJ, Watson AMD, Thomas MC, Jandeleit-Dahm KAM.

Diabetes. 2018 May;67(5):785-790. doi: 10.2337/dbi18-0010. Review.

12.

SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus.

Gill A, Gray SP, Jandeleit-Dahm KA, Watson AMD.

Curr Diabetes Rev. 2019;15(5):349-356. doi: 10.2174/1573399814666180417121246.

PMID:
29663893
13.

Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease.

Brennan EP, Mohan M, McClelland A, Tikellis C, Ziemann M, Kaspi A, Gray SP, Pickering R, Tan SM, Ali-Shah ST, Guiry PJ, El-Osta A, Jandeleit-Dahm K, Cooper ME, Godson C, Kantharidis P.

J Am Soc Nephrol. 2018 May;29(5):1437-1448. doi: 10.1681/ASN.2017101112. Epub 2018 Feb 28.

14.

GLP-1 receptor agonists: An example of the challenge for animal models to predict plaque instability/rupture and cardiovascular outcomes.

Ying YL, Chen YC, Jandeleit-Dahm K, Peter K.

Atherosclerosis. 2017 Oct;265:250-252. doi: 10.1016/j.atherosclerosis.2017.08.006. Epub 2017 Aug 18. No abstract available.

PMID:
28870630
15.

NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy.

Jha JC, Banal C, Okabe J, Gray SP, Hettige T, Chow BSM, Thallas-Bonke V, De Vos L, Holterman CE, Coughlan MT, Power DA, Skene A, Ekinci EI, Cooper ME, Touyz RM, Kennedy CR, Jandeleit-Dahm K.

Diabetes. 2017 Oct;66(10):2691-2703. doi: 10.2337/db16-1585. Epub 2017 Jul 26.

16.

Protective Effect of let-7 miRNA Family in Regulating Inflammation in Diabetes-Associated Atherosclerosis.

Brennan E, Wang B, McClelland A, Mohan M, Marai M, Beuscart O, Derouiche S, Gray S, Pickering R, Tikellis C, de Gaetano M, Barry M, Belton O, Ali-Shah ST, Guiry P, Jandeleit-Dahm KAM, Cooper ME, Godson C, Kantharidis P.

Diabetes. 2017 Aug;66(8):2266-2277. doi: 10.2337/db16-1405. Epub 2017 May 9.

17.

The emerging role of NADPH oxidase NOX5 in vascular disease.

Jha JC, Watson AMD, Mathew G, de Vos LC, Jandeleit-Dahm K.

Clin Sci (Lond). 2017 May 1;131(10):981-990. doi: 10.1042/CS20160846. Review.

PMID:
28473473
18.

Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease.

Gray SP, Jha JC, Kennedy K, van Bommel E, Chew P, Szyndralewiez C, Touyz RM, Schmidt HHHW, Cooper ME, Jandeleit-Dahm KAM.

Diabetologia. 2017 May;60(5):927-937. doi: 10.1007/s00125-017-4215-5. Epub 2017 Feb 3.

PMID:
28160092
19.

Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling-Are Useful Drugs Already Available?

Arthur JF, Jandeleit-Dahm K, Andrews RK.

Diabetes. 2017 Jan;66(1):7-13. doi: 10.2337/db16-1098.

20.

NOX4-derived reactive oxygen species limit fibrosis and inhibit proliferation of vascular smooth muscle cells in diabetic atherosclerosis.

Di Marco E, Gray SP, Kennedy K, Szyndralewiez C, Lyle AN, Lassègue B, Griendling KK, Cooper ME, Schmidt HHHW, Jandeleit-Dahm KAM.

Free Radic Biol Med. 2016 Aug;97:556-567. doi: 10.1016/j.freeradbiomed.2016.07.013. Epub 2016 Jul 19.

21.

Differential effects of NOX4 and NOX1 on immune cell-mediated inflammation in the aortic sinus of diabetic ApoE-/- mice.

Di Marco E, Gray SP, Chew P, Kennedy K, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

Clin Sci (Lond). 2016 Aug 1;130(15):1363-74. doi: 10.1042/CS20160249. Epub 2016 May 17.

PMID:
27190136
22.

The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.

Chow BS, Koulis C, Krishnaswamy P, Steckelings UM, Unger T, Cooper ME, Jandeleit-Dahm KA, Allen TJ.

Diabetologia. 2016 Aug;59(8):1778-90. doi: 10.1007/s00125-016-3977-5. Epub 2016 May 11.

PMID:
27168137
23.

Diabetes and Kidney Disease: Role of Oxidative Stress.

Jha JC, Banal C, Chow BS, Cooper ME, Jandeleit-Dahm K.

Antioxid Redox Signal. 2016 Oct 20;25(12):657-684. Epub 2016 Apr 1. Review.

24.

Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling.

Gray SP, Di Marco E, Kennedy K, Chew P, Okabe J, El-Osta A, Calkin AC, Biessen EA, Touyz RM, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):295-307. doi: 10.1161/ATVBAHA.115.307012. Epub 2015 Dec 29.

PMID:
26715682
25.

RAGE Against the ABCs.

Allen TJ, Murphy AJ, Jandeleit-Dahm KA.

Diabetes. 2015 Dec;64(12):3981-3. doi: 10.2337/dbi15-0015. No abstract available.

26.

The role of NADPH oxidase in vascular disease--hypertension, atherosclerosis & stroke.

Gray SP, Jandeleit-Dahm KA.

Curr Pharm Des. 2015;21(41):5933-44. Review.

PMID:
26510435
27.

Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.

Jha JC, Thallas-Bonke V, Banal C, Gray SP, Chow BS, Ramm G, Quaggin SE, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

Diabetologia. 2016 Feb;59(2):379-89. doi: 10.1007/s00125-015-3796-0. Epub 2015 Oct 28.

28.

Linking RAGE and Nox in diabetic micro- and macrovascular complications.

Koulis C, Watson AM, Gray SP, Jandeleit-Dahm KA.

Diabetes Metab. 2015 Sep;41(4):272-81. doi: 10.1016/j.diabet.2015.01.006. Epub 2015 Aug 29. Review.

PMID:
26323666
29.

CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis.

Chu PY, Walder K, Horlock D, Williams D, Nelson E, Byrne M, Jandeleit-Dahm K, Zimmet P, Kaye DM.

PLoS One. 2015 Jul 27;10(7):e0133616. doi: 10.1371/journal.pone.0133616. eCollection 2015.

30.

HMGB1 binds to activated platelets via the receptor for advanced glycation end products and is present in platelet rich human coronary artery thrombi.

Ahrens I, Chen YC, Topcic D, Bode M, Haenel D, Hagemeyer CE, Seeba H, Duerschmied D, Bassler N, Jandeleit-Dahm KA, Sweet MJ, Agrotis A, Bobik A, Peter K.

Thromb Haemost. 2015 Nov;114(5):994-1003. doi: 10.1160/TH14-12-1073. Epub 2015 Jul 23.

PMID:
26202300
31.

Are reactive oxygen species still the basis for diabetic complications?

Di Marco E, Jha JC, Sharma A, Wilkinson-Berka JL, Jandeleit-Dahm KA, de Haan JB.

Clin Sci (Lond). 2015 Jul;129(2):199-216. doi: 10.1042/CS20150093. Review.

PMID:
25927680
32.

AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy.

Koulis C, Chow BS, McKelvey M, Steckelings UM, Unger T, Thallas-Bonke V, Thomas MC, Cooper ME, Jandeleit-Dahm KA, Allen TJ.

Hypertension. 2015 May;65(5):1073-81. doi: 10.1161/HYPERTENSIONAHA.115.05204. Epub 2015 Mar 16.

PMID:
25776077
33.

Beyond Glycosuria: Exploring the intrarenal effects of SGLT₋₂ inhibition in diabetes.

Thomas MC, Jandeleit-Dahm K, Bonnet F.

Diabetes Metab. 2014 Dec;40(6 Suppl 1):S17-22. doi: 10.1016/S1262-3636(14)72691-6. Review.

PMID:
25554067
34.

Diabetic kidney disease.

Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KA, Zoungas S, Rossing P, Groop PH, Cooper ME.

Nat Rev Dis Primers. 2015 Jul 30;1:15018. doi: 10.1038/nrdp.2015.18. Review.

PMID:
27188921
35.

Nox-4 and progressive kidney disease.

Thallas-Bonke V, Jandeleit-Dahm KA, Cooper ME.

Curr Opin Nephrol Hypertens. 2015 Jan;24(1):74-80. doi: 10.1097/MNH.0000000000000082. Review.

PMID:
25402870
36.

Nox-4 deletion reduces oxidative stress and injury by PKC-α-associated mechanisms in diabetic nephropathy.

Thallas-Bonke V, Jha JC, Gray SP, Barit D, Haller H, Schmidt HH, Coughlan MT, Cooper ME, Forbes JM, Jandeleit-Dahm KA.

Physiol Rep. 2014 Nov 3;2(11). pii: e12192. doi: 10.14814/phy2.12192. Print 2014 Nov 1.

37.

Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function?

Kraakman MJ, Murphy AJ, Jandeleit-Dahm K, Kammoun HL.

Front Immunol. 2014 Sep 26;5:470. doi: 10.3389/fimmu.2014.00470. eCollection 2014. Review.

38.

Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice.

Watson AM, Li J, Samijono D, Bierhaus A, Thomas MC, Jandeleit-Dahm KA, Cooper ME.

Atherosclerosis. 2014 Aug;235(2):444-8. doi: 10.1016/j.atherosclerosis.2014.05.945. Epub 2014 Jun 4.

PMID:
24945577
39.

Auditory neuropathy in individuals with Type 1 diabetes.

Rance G, Chisari D, O'Hare F, Roberts L, Shaw J, Jandeleit-Dahm K, Szmulewicz D.

J Neurol. 2014 Aug;261(8):1531-6. doi: 10.1007/s00415-014-7371-2. Epub 2014 May 21.

PMID:
24846202
40.

Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes.

Tikellis C, Pickering RJ, Tsorotes D, Huet O, Cooper ME, Jandeleit-Dahm K, Thomas MC.

Diabetes. 2014 Nov;63(11):3915-25. doi: 10.2337/db13-0932. Epub 2014 May 8.

41.

New insights into the use of biomarkers of diabetic nephropathy.

Jha JC, Jandeleit-Dahm KA, Cooper ME.

Adv Chronic Kidney Dis. 2014 May;21(3):318-26. doi: 10.1053/j.ackd.2014.03.008. Review.

PMID:
24780461
42.

Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosis.

Koulis C, Kanellakis P, Pickering RJ, Tsorotes D, Murphy AJ, Gray SP, Thomas MC, Jandeleit-Dahm KA, Cooper ME, Allen TJ.

Clin Sci (Lond). 2014 Oct;127(7):485-97. doi: 10.1042/CS20140045.

PMID:
24724734
43.

The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.

Gray SP, Jandeleit-Dahm K.

J Mol Med (Berl). 2014 May;92(5):441-52. doi: 10.1007/s00109-014-1146-1. Epub 2014 Apr 1. Review.

PMID:
24687627
44.

NAD(P)H oxidase isoforms as therapeutic targets for diabetic complications.

Gray SP, Jha JC, Di Marco E, Jandeleit-Dahm KA.

Expert Rev Endocrinol Metab. 2014 Mar;9(2):111-122. doi: 10.1586/17446651.2014.887984. Epub 2014 Feb 10.

PMID:
30743754
45.

Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.

Jha JC, Gray SP, Barit D, Okabe J, El-Osta A, Namikoshi T, Thallas-Bonke V, Wingler K, Szyndralewiez C, Heitz F, Touyz RM, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

J Am Soc Nephrol. 2014 Jun;25(6):1237-54. doi: 10.1681/ASN.2013070810. Epub 2014 Feb 7.

46.

Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice.

Koulis C, Chen YC, Hausding C, Ahrens I, Kyaw TS, Tay C, Allen T, Jandeleit-Dahm K, Sweet MJ, Akira S, Bobik A, Peter K, Agrotis A.

Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):516-25. doi: 10.1161/ATVBAHA.113.302407. Epub 2014 Jan 16.

PMID:
24436372
47.

Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe(-/-) mice.

Di Marco E, Gray SP, Chew P, Koulis C, Ziegler A, Szyndralewiez C, Touyz RM, Schmidt HH, Cooper ME, Slattery R, Jandeleit-Dahm KA.

Diabetologia. 2014 Mar;57(3):633-42. doi: 10.1007/s00125-013-3118-3. Epub 2013 Nov 30.

PMID:
24292634
48.

Comment on: Sukumar et al. Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction. Diabetes 2013;62:2130-2134.

Jandeleit-Dahm KA, Schmidt HH.

Diabetes. 2013 Dec;62(12):e30. doi: 10.2337/db13-1286. No abstract available.

49.

Diabetic nephropathy: diagnosis and treatment.

Fineberg D, Jandeleit-Dahm KA, Cooper ME.

Nat Rev Endocrinol. 2013 Dec;9(12):713-23. doi: 10.1038/nrendo.2013.184. Epub 2013 Oct 8. Review.

PMID:
24100266
50.

Transforming growth factor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b.

Wang B, Jha JC, Hagiwara S, McClelland AD, Jandeleit-Dahm K, Thomas MC, Cooper ME, Kantharidis P.

Kidney Int. 2014 Feb;85(2):352-61. doi: 10.1038/ki.2013.372. Epub 2013 Oct 2.

Supplemental Content

Loading ...
Support Center